Inozyme Pharma Inc
(NAS:INZY)
$
5.77
0.31 (5.68%)
Market Cap: 356.90 Mil
Enterprise Value: 216.98 Mil
PE Ratio: 0
PB Ratio: 3.01
GF Score: 40/100 Inozyme Pharma Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023 / 01:30PM GMT
Release Date Price:
$6
(+2.39%)
Joey Stringer
Needham & Company - Analyst
Good morning, everyone. Thank you for joining the 22nd Annual Needham Healthcare Conference. My name is Joey Stringer, and I'm one of the biotech analysts at Needham & Company. It's my pleasure to introduce our next presenting company, its Inozyme Pharma. Joining us today from Inozyme is CEO, Doug Treco.
For those of you joining us on the webcast, if you want to ask a question, you can do so at any time. You can submit a question using the chat box feature at the bottom of your screen. So with that, we'll get started. Doug, great to see you and thank you so much for joining us today.
Doug Treco
Inozyme Pharma, Inc. - CEO & Chairman
Thanks, Joey.
Questions & Answers
Joey Stringer
Needham & Company - Analyst
Doug, you assumed the CEO role just recently, just this month. Any change in the corporate strategy or vision for Inozyme going forward?
Doug Treco
Inozyme Pharma, Inc. - CEO & Chairman
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot